We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain called the striatum.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
34
1 and 5 mg tablets, 6 mg single dose
matching placebo tablets, single dose
1 mg tablets, 3 mg single dose
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Pfizer Investigational Site
New Haven, Connecticut, United States
Glucose metabolic rates in striatum using standard Region of Interest (ROI) analysis method.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
Whole brain glucose metabolic rate.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
Relative glucose metabolic rate in striatum.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
Glucose metabolic rate in striatal subregions: putamen and caudate nucleus.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
Relative glucose metabolic rate in striatal subregions: putamen and caudate nucleus.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
Glucose metabolic rate in striatum determined using data-driven ROI analysis method.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
Relative glucose metabolic rate in striatum determined using data-driven ROI analysis method.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
Effect size comparison between standard ROI and data-driven ROI analysis methods using both regional glucose metabolic rate and relative regional glucose metabolic rate.
Time frame: Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
5 mg tablets, 15 mg single dose
matching placebo tablets, single dose